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Immunoresponsive Tissue-Engineered Oral Mucosal
Equivalents Containing Macrophages
Bethany Ollington, MSc,i Helen E. Colley, PhD,ii and Craig Murdoch, PhDiii
Macrophages play a key role in orchestrating the host immune response toward invading organisms or non-self
molecules in the oral mucosa. Three-dimensional (3D) oral mucosal equivalents (OME) containing oral fibro-
blasts and keratinocytes are used extensively to mimic the human oral mucosa where they have been employed
to examine innate immune responses to both bacterial and fungal pathogens as well as to biomaterials. Although
the presence of immune cells is critical in generating an immune response, very few studies have incorporated
leukocytes into OME, and to date, none have contained primary human macrophages. In this study, we report
the generation of an immunocompetent OME to investigate immune responses toward bacterial challenge.
Primary human monocyte-derived macrophages (MDM) were as responsive to bacterial lipopolysaccharide
(LPS) challenge when cultured within a 3D hydrogel in terms of proinflammatory cytokine (IL-6, CXCL8, and
TNF-a) gene expression and protein secretion compared with culture as two-dimensional monolayers. MDM
were incorporated into a type 1 collagen hydrogel along with oral fibroblasts and the apical surface seeded with
oral keratinocytes to generate an MDM-containing OME. Full-thickness MDM-OME displayed a stratified squa-
mous epithelium and a fibroblast-populated connective tissue containing CD68-positive MDM that could be
readily isolated to a single-cell population for further analysis by collagenase treatment followed by flow cytom-
etry. When stimulated with LPS, MDM-OME responded with increased proinflammatory cytokine secretion,
most notably for TNF-a that increased 12-fold when compared with OME alone. Moreover, this proinflamma-
tory response was inhibited by pretreatment with dexamethasone, showing that MDM-OME are also amenable
to drug treatment. Dual-labeled immunofluorescence confocal microscopy revealed that MDM were the sole
source of TNF-a production within MDM-OME. These data show functional activity of MDM-OME and illus-
trate their usefulness for investigations aimed at monitoring the immune response of the oral mucosa to path-
ogens, biomaterials, and for tissue toxicity and anti-inflammatory drug delivery studies.
Keywords: oral mucosa, tissue engineering, macrophage, infection, immune response
Impact Statement
Three-dimensional in vitro models of the oral mucosa have been used extensively to investigate the host response to
pathogens, but, to date, few have contained primary leukocytes. In this report, we describe the successful incorporation of
primary human macrophages into oral mucosal equivalents (OME). These macrophage-containing models were histolog-
ically similar to the oral mucosa and immunoresponsive to bacterial lipopolysaccharides by upregulation of key proin-
flammatory markers. These advanced OME will significantly aid research into host–pathogen interaction, biomaterial
toxicity, and drug delivery studies where the presence of an immune cell component is critical to better represent host oral
tissue.
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T issue-engineered oral mucosal equivalents (OME)have been used extensively to study the oral mucosa
as improved model systems compared with in vitro cultured
oral keratinocytes grown as two-dimensional (2D) mono-
layers.1 OME can be in the form of a reconstituted human
epithelium where keratinocytes alone are cultured on a po-
rous membrane or as full-thickness cultures that are compo-
sed of a fibroblast-populated connective tissue topped with
a stratified squamous oral epithelium. Collectively, these
OME have been used in numerous studies to study, among
others, oral mucosal microbial infection,2,3 wound heal-
ing,4,5 cancer progression,6,7 and oral mucositis,8,9 as well as
to examine the response of the oral mucosa to biomaterials
and to monitor toxicity, drug delivery, and efficacy.10–12
Resident and recruited immune cells are essential for
maintenance of oral tissue and are critical in driving host
responses to external insults, while dysregulation of the im-
mune response can cause chronic conditions leading to de-
bilitating oral lesions or poor outcomes in the case of oral
squamous cell carcinoma.13–15 Macrophages are key innate
immune cells found in virtually all tissues. These leukocytes
directly protect from invading foreign organisms by phago-
cytosis, presenting antigens to T lymphocytes, and secreting
an array of inflammatory factors that orchestrate the immune
response. Macrophage activation can occur through recogni-
tion of pathogen-associated molecular patterns, for example,
in response to lipopolysaccharides (LPS) of gram-negative
bacteria by cell surface pattern recognition receptors, such
as CD14 and Toll-like receptors. This interaction induces
intracellular signaling leading to increased gene expression
and secretion of proinflammatory cytokines such as TNF-a16
that can be inhibited by anti-inflammatory therapeutics such
as glucocorticoids.17 Addition of immune cells, such as mac-
rophages, to current OME would increase their sensitivity to
detect and respond to foreign molecules, making them more
representative of the native oral mucosa.
Previous studies have generated immune oral gingival
models by incorporating primary monocytes, peripheral blood
mononuclear cells, or myeloid cancer cell lines (MonoMac-6
[MM6], U937, or THP-1 cells) and by observing changes in
inflammatory markers and proteases in response to bacterial
LPS,18–21 bacterial biofilms,22 or X-ray treatment.23 While
the use of myeloid cancer cell lines presents fewer technical
limitations and reproducibility compared with primary im-
mune cells, there is good evidence that their phenotype and
function is markedly altered compared with primary cells,
with the often used THP-1 cells shown to express aberrant
levels of key macrophage phenotypic markers and thus re-
spond differently to stimuli.24 Moreover, peripheral blood
monocytes very rapidly differentiate into macrophages upon
crossing the vasculature as they migrate into tissues and
so incorporation of macrophages rather than monocytes into
OME is more desirable. Therefore, use of primary macro-
phages is preferential for use in in vitro OME as these cells
better represent the innate immune component of human
tissue.
Here, we describe the generation of a tissue-engineered
immune model of nonkeratinized oral mucosa containing
primary human monocyte-derived macrophages (MDM).
These immune OME produced functional responses upon
stimulation with Escherichia coli LPS in the form of in-
creased secretion of proinflammatory cytokines that were
inhibited by dexamethasone treatment. These OME will be
extremely beneficial for studies aimed at investigating mac-
rophage behavior in disease and cellular toxicity, as well as




Unless otherwise stated, all reagents were purchased from
Sigma–Aldrich, United Kingdom.
Cell isolation and culture
MDM were differentiated from primary human monocy-
tes as previously described.25 Briefly, buffy coats obtained
from the National Blood Service, United Kingdom (Ethical
Approval No. 012597) were diluted 1:1 in Hank’s balanced
salt solution (without Ca2+ and Mg2+) and mononuclear cells
separated by density-gradient centrifugation using Ficoll
Paque Plus (GE Healthcare, United Kingdom). Monocytes
were purified by plastic adherence and differentiated to
MDM by 7 days culture in Iscove’s modified Dulbecco’s
medium supplemented with 2% human AB serum, 2mM
l-glutamine, 100 IU/mL penicillin, and 100 mg/mL strepto-
mycin. Differentiation of monocyte to MDM was confirmed
by cell morphology, gene expression, and cell surface pro-
tein abundance of key differentiation markers.
FNB6-hTERT immortalized oral keratinocytes (Ximbio,
United Kingdom)26 were cultured in flavin- and adenine-
enriched medium consisting of Dulbecco’s modified Eagle’s
medium (DMEM) and Ham’s F12 medium in a 3:1 (v/v)
ratio supplemented with 10% (v/v) fetal bovine serum (FBS),
10 ng/mL epidermal growth factor, 0.18mM adenine, 5mg/mL
insulin, 5 mg/mL transferrin, 2mM L-glutamine, 0.2 nM tri-
iodothyronine, 0.625mg/mL amphotericin B, 100 IU/mL
penicillin, and 100mg/mL streptomycin. Normal oral fibro-
blasts (NOF) were isolated from the connective tissue of
biopsies obtained from the oral mucosa of patients during
routine dental procedures with written informed consent
(Ethical Approval No. 09/H1308/66) and cultured in DMEM
supplemented with 10% v/v FBS, 2mM L-glutamine, 100
IU/mL penicillin, and 100mg/mL streptomycin.6
Generation of MDM-OME
OME were constructed as previously described.27 In brief,
NOF were mixed with rat tail type I collagen (2· 105 NOF/
mL collagen), and 1mL aliquoted into 12mm cell culture
transwell inserts (0.4mm Polyethylene Terephthalate; Merck
Millipore, USA) and the cell-populated collagen hydrogels
incubated in a humidified atmosphere at 37C for 2 h to
solidify. FNB6-hTERT cells (5 · 105) were then seeded on
the surface of the collagen hydrogel and cultured submerged
for 2 days, after which the models were raised to an air-to-
liquid interface and cultured for a further 10 days. To gen-
erate MDM-OME, 7-day MDM (1 · 106 MDM/OME) were
added to collagen hydrogels alongside NOF. A single batch
of collagen was used in all experiments that contained
<0.2 EU/mL endotoxin when quantified by limulus amebo-
cyte lysate assay (Thermo Fisher Scientific, United Kingdom).
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Simulation of MDM and MDM-OME
LPS from E. coli 0111:B4 (500 ng per 1 · 106 MDM;
Invivogen, USA) was diluted in culture medium and used to
treat MDM for 24 h to stimulate an inflammatory response.
Where indicated, MDM were pretreated for 4 h with 1mg/mL
dexamethasone (Abcam, USA) diluted in culture medium
before LPS stimulation to inhibit the inflammatory response.
MDM or MDM-OME incubated with medium alone were
used as unstimulated controls.
Protein secretion and gene expression analysis
Following 24 h incubation with LPS, secretion of the in-
flammatory cytokines TNF-a, CXCL8, and IL-6 into con-
ditioned media were quantified by ELISA (Human Duoset;
R&D systems, USA) and cell toxicity measured by release
of lactate dehydrogenase (CytoTox96; Promega, United
Kingdom). Total RNA was extracted following the manu-
facturer’s instructions (Monarch Total RNA Miniprep Kit;
New England Biolabs, United Kingdom) and then reverse
transcribed to cDNA (High-Capacity RT Kit; Thermo Fisher
Scientific), with the amount of RNA used kept consistent
within experiments. Quantitative polymerase chain reaction
(qPCR) was performed with TaqMan gene expression assays
using VIC-labeled b2-microglobulin probe (hs00187842_m1)
as a reference control alongside FAM-labeled target probes
for: CD11c (hs00174217_m1), CD14 (hs02621496_s1), CD36
(hs01567185_m1), CD80 (hs00175478_m1), CD163
(hs00174705_m1), CD206 (hs00267207_m1), carboxypeptidase
M (CPM) (hs01074151_m1), HLA-DRA (hs00219575_m1), vi-
mentin (hs00958111_m1), CXCL8 (hs00174103_m1), IL-6
(hs00174131_m1), and TNF-a (hs01113624_g1). Expression of
the target gene was normalized to the abundance of the control
gene transcript, b-2-microglobulin.
Flow cytometry
MDMcultured asmonolayer were removed from the culture
dish using a cell scraper and resuspended at 5· 105 cells/mL in
FACS buffer (phosphate-buffered saline [PBS], pH 7.2; 0.1%
bovine serum albumin; 0.1% sodium azide). Cells were incu-
bated on ice for 5min in FACS buffer containing 5mL Fc
blocking reagent (Miltenyi Biotech, Germany) and then incu-
bated for 20min at 4C in the dark with one of the following
allophycocyanin (APC)-conjugated antibodies: Mouse IgG
control (17-4714-81; eBioscience, USA), CD11c (130-114-
110; Miltenyi Biotech), CD14 (17-0149-42; eBioscience),
CD36 (130-095-475; Miltenyi Biotech), and HLA-DR (130-
111-943; Miltenyi Biotech). MDM-OMEwere digested by 1 h
incubation with 2mg/mL collagenase type 1 (Life Technol-
ogies, UK) at 37C and passed through a cell strainer (Corning,
UK) to obtain single-cell suspensions. The LIVE/DEAD flex-
ible blue stain (Thermo Fisher Scientific) was used, as per
manufacturer’s instructions, to measure and exclude dead cells
from the analysis andAPC-conjugatedCD11c antibody used to
identifyMDM. Flow cytometrywas performed using an LSRII
(BD Biosciences, USA) and analyzed by the FlowJo software
v10.7 (BD Biosciences).
Histological and immunohistochemical analysis
MDM-OME were washed with PBS, fixed in 10% neutral
buffered formalin for 24 h, and paraffin-wax embedded
using standard histology procedures. Sections (5mm) were cut
using a Leica RM2235 microtome (Leica Microsystems,
Germany) and mounted on Superfrost Plus slides (Thermo
Fisher Scientific). Sections stained with hematoxylin and
eosin were mounted in dibutylphthalate polystyrene xylene
and imaged using an Olympus BX51 microscope with cell-
Sens Imaging Software (Olympus GmbH, Germany). For
immunofluorescence staining, sections were dewaxed, dehy-
drated, and high-temperature Tris/EDTA buffer (pH 9) anti-
gen retrieval performed, then blocked with goat serum for
20min. Sections were incubated with mouse anti-human
CD68 (0.4mg/mL; clone KP1, Abcam ab955) followed by
fluorescein isothiocyanate-conjugated goat anti-mouse F(ab)
IgG (1mg/mL, Abcam ab6669) and recombinant rabbit anti-
human TNF-a (8mg/mL, 17590-1-AP, Proteintech, UK) fol-
lowed by Cy3-conjugated donkey anti-rabbit IgG (Jackson
Immunoresearch, USA) for 1 h at room temperature, with
PBS washing between incubations. After staining, slides were
mounted with Prolong Diamond anti-fade (Thermo Fisher
Scientific), cured for 24 h at room temperature in the dark and
imaged using a Zeiss Axioplan 2 microscope with the Image
ProPlus v7.0.1 software (Media Cybernetics Inc., MD, USA).
Statistical analysis
All data are presented as mean – standard deviation of
at least three independent biological experiments. Statistical
analysis was undertaken using GraphPad Prism (v9.0.2,
GraphPad Software). Pairwise comparisons were performed
using Students t-test and group-wise comparisons using
one-way analysis of variance followed by Tukey’s post-hoc
multiple comparisons test. Differences between groups was
considered significant when p < 0.05.
Experiment
MDM characterization, and their activation
and inhibition in 2D monolayer and three-dimensional
collagen hydrogels
Monocytes isolated from peripheral blood were differen-
tiated to MDM in 2D culture as determined by changes to
cell morphology, such as increased cell size and nuclear to
cytoplasm ratio (Supplementary Fig. S1A, B), and altera-
tions in the gene expression and cell surface protein abun-
dance of key differentiation markers. These included the
presence of vimentin and CD11c gene expression, increased
gene expression of CPM and CD36, along with decreased
gene expression of CD14, as the monocytes differentiate to
MDM (Supplementary Fig. S1C). In addition, increased cell
surface abundance of CD11c, CD36, and HLA-DR as well
as decreased abundance of CD14 by MDM compared with
monocytes was observed by flow cytometry (Supplementary
Fig. S1D), in line with previous reports.28–30
LPS isolated from E. coli was used to show a functional
response of 2D-cultured MDM to bacterial-mediated chal-
lenge, whereas the anti-inflammatory glucocorticoid, dexa-
methasone, inhibited LPS-induced protein secretion of
TNF-a, CXCL8, and IL-6 in a dose-dependent manner
(Supplementary Fig. S2A–C). Inhibition of cytokine secre-
tion by pretreatment with dexamethasone was significant at
concentrations ranging from 0.1 to 100mg/mL at both 4 and
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24 h without affecting MDM cell viability compared with
untreated controls (Supplementary Fig. S2A–D). Treatment
of MDM with 1 mg/mL dexamethasone for 4 h was used in
subsequent experiments.
To determine the MDM function in three-dimensional
(3D) as well as 2D, MDM were cultured as monolayer or
within a type I collagen hydrogel to mimic the connective
tissue component of the oral mucosa. In 2D monolayer cul-
tures, LPS treatment significantly increased gene expres-
sion of inflammatory mediators CD80 ( p < 0.01), CXCL8
( p < 0.05), and IL-6 ( p< 0.01) compared with unstimulated
controls (Fig. 1A). Expression of CD206 was significantly
decreased upon LPS stimulation ( p < 0.05) while that of
TNF-a remained unchanged. For CD80, TNF-a, CXCL8, and
IL-6 changes in gene expression were significantly inhibited
by pretreatment with dexamethasone ( p < 0.05; Fig. 1A). In
most instances, the functional activity of MDM in 3D cul-
ture replicated those observed in 2D. Once again, signifi-
cantly increased gene expression was observed for CD80
( p < 0.05), CXCL8 ( p < 0.01), and IL-6 ( p < 0.01) upon LPS
stimulation that was inhibited by dexamethasone pretreat-
ment ( p £ 0.05; Fig. 1B). In contrast to 2D cultures, no dif-
ferences in gene expression were found with CD206 or
TNF-a between treated MDM and controls when cultured in
3D hydrogels (Fig. 1B). Analysis of MDM protein secretion
upon LPS and dexamethasone treatment was consistently
similar for 2D and 3D cultures. Here, secretion of TNF-a,
CXCL8, and IL-6 was significantly increased by LPS for 2D
( p < 0.001) and 3D ( p £ 0.01) cultures, and these increased
levels were significantly inhibited back to control levels by
pretreatment with dexamethasone (£ 0.05 for 2D and 3D,
Fig. 1C, D). These data suggest that MDM response to LPS
or glucocorticoids is retained in a 3D environment similar
to that observed in 2D in vitro culture.
FIG. 1. Activation of MDM in monolayer and 3D collagen hydrogels. MDM were cultured as monolayers (A) or within
3D collagen hydrogels (B) for 24 h before incubation with E. coli LPS (500ng/106 MDM) for 24 h or preincubated with Dex
(1mg/mL) for 4 h before addition of E. coli LPS for 24 h, controls received vehicle only for 24 h. Gene expression was analyzed
by qPCR for CD80, CD206, TNF-a, CXCL8, and IL-6, and expression calculated relative to the reference control B2M.
Secretion of TNF-a (C), CXCL8 (D), and IL-6 (E) was measured by ELISA. Data are presented as mean–SD with statistically
significance differences determined using one-way ANOVA and compared with untreated control. *p< 0.05, **p< 0.01,
***p< 0.005; n= 3. 3D, three-dimensional; ANOVA, analysis of variance; B2M, b2-microglobulin, Dex, dexamethasone;
E. coli, Escherichia coli; ELISA, enzyme-linked immunosorbent assay; LPS, lipopolysaccharides; MDM, monocyte-derived
macrophages; qPCR, quantitative polymerase chain reaction; SD, standard deviation. Color images are available online.
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Generation and histological validation of MDM-OME
Histological analysis of OME and MDM-OME revealed
that both models were composed of a nonkeratinized, strat-
ified squamous epithelium consisting of oral keratinocytes that
progressively differentiate toward the apical surface, along
with a cell-populated connective tissue (Fig. 2A, B). Immu-
nopositive intracellular staining for the well-characterized
macrophage marker CD68 identified MDM that were disper-
sed throughout the connective tissue component of MDM-
OME, but not OME (Fig. 2E, F). We have extensively
characterized OME previously in terms of their histological
markers and ultrastructure and so analysis was not per-
formed in this study.27,31 MDM-OME displayed proliferat-
ing (ki67+) keratinocytes in the basal layer of the epithelium
(Fig. 2C) that was also highly immunoreactive to the pan-
cytokeratin antibody AE1/3 confirming the presence of dif-
ferentiating keratinocytes throughout the epithelium (Fig. 2D).
Immunopositive E-cadherin staining was observed at the
keratinocyte cell–cell junctions, indicating a well-formed
epithelial network (Fig. 2G), whereas vimentin was obser-
ved in both the fibroblasts and MDM within the connective
tissue, as well as within some of the basal keratinocytes
(Fig. 2H).
MDM single-cell analysis and viability
within MDM-OME
Following collagenase disaggregation of the hydrogel, an
MDM-specific flow cytometric gating strategy was emplo-
yed to measure the MDM viability within MDM-OME.
Cells were dual stained with a fluorescent viability dye and
an APC-conjugated monoclonal antibody for pan-monocyte-
derived cell marker, CD11c, to specifically identify MDM
within the heterogeneous cell population. When segregated
into CD11c– and CD11c+ cells, MDM-OME contained
32% – 10% CD11c+ MDM, whereas OME contained <1%
CD11c+ due to nonspecific antibody staining (Fig. 3A, B).
The viability of the CD11c– keratinocyte and fibroblast
population was 68% – 4% and was similar to the viability of
this cell population in OME (73% – 4%), whereas the MDM
CD11c+ viability in MDM-OME was 67%– 8% (Fig. 3C, D).
MDM-OME respond to LPS by secretion of TNF-a
To assess the MDM function within MDM-OME, chan-
ges in gene expression and inflammatory cytokine secretion
were quantified in response to 24 h LPS treatment, with or
without 4 h dexamethasone pretreatment. As expected, gene
expression of the macrophage-specific markers CD80 and
CD206 was not detected in OME (Fig. 4A). Gene expression
was detected for CD163, TNF-a, CXCL8, and IL-6, but lev-
els of expression were similar between treatments for all
genes (Fig. 4A). In MDM-OME, gene expression of the mac-
rophage markers CD80 and CD206 was observed, but there
were no differences between control and treated samples, as
was the case for TNF-a (Fig. 4B). Pretreatment with dexa-
methasone significantly increased gene expression of CD163
but only in the presence of LPS ( p < 0.05). Gene expression
for CXCL8 was significantly increased ( p < 0.01) in LPS-
treated MDM-OME compared with unstimulated controls,
and levels of this chemokine were inhibited by pretreatment
with dexamethasone ( p < 0.01; Fig. 4B), whereas mRNA
levels of IL-6 were similar in control and LPS-treated sam-
ples but significantly reduced by dexamethasone ( p < 0.05;
Fig. 4B).
The conditioned medium was also assessed for secreted
TNF-a, CXCL8, and IL-6 from MDM-OME and compared
with OME. No differences in TNF-a were observed in OME
between any treatments, whereas a 10-fold increase was ob-
served in TNF-a levels of LPS-treated MDM-OME compared
with control MDM-OME that were significantly inhibited
by dexamethasone pretreatment ( p < 0.01, Fig. 4C). CXCL8
released by LPS-treated MDM-OME was significantly
FIG. 2. Histological characterization of MDM-OME. Models were cultured for 10 days at air-to-liquid interface and
analyzed by histology with hematoxylin and eosin staining (A, B) and immunohistochemistry for immunopositive
expression of ki67 (C) cytokeratin (AE1/3) (D), CD68 (E, F), E-cadherin (G), and vimentin (H). Images presented as
representative from at least three independent experiments. Scale bar = 100mm and 20 mm for the inlay box in (F). OME,
oral mucosa equivalent. Color images are available online.
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( p < 0.05) elevated in comparison to all OME irrespective of
treatment but were not significantly different from control or
dexamethasone-treated MDM-OME (Fig. 4D), whereas IL-6
levels were similar for all samples tested (Fig. 4E). These
data suggest that LPS induced a robust TNF-a response but
only when MDM were present in the OME. Dual-labeled
immunofluorescence microscopy for CD68 and TNF-a
confirmed that immunopositive staining for TNF-a was in-
creased in LPS-treated MDM-OME and reduced by dexa-
methasone (Fig. 5A). Moreover, TNF-a co-localized with
that of CD68-positive cells and not NOF in LPS-treated
MDM-OME (Fig. 5B), indicating that LPS-mediated TNF-a
release within the MDM-OME 3D models is MDM-specific.
Discussion
The importance of macrophages in initiating an immune
response in the oral mucosa as well as their significance in
multiple oral diseases is well recognized.13,14,32 However,
macrophage responses to external stimuli are often exam-
ined in isolation to other cells, more often than not as 2D
monolayer cultures where cell surface adhesion-matrix con-
tacts are limited. In vivo macrophages experience life in
a 3D context, therefore developing 3D tissue-engineered
in vitro models with increasing complexity is of particular
importance if we are to fully understand how cells function
in native tissue. Although the use of tissue-engineered OME
is now relatively common in oral mucosal studies, the in-
corporation of additional cells into these systems, especially
immune cells, is lacking. Here, we describe the construction
of tissue-engineered OME that contain functional primary
human macrophages.
To date, very few studies have attempted to include mac-
rophages cells into 3D oral mucosal models. The 3D co-
culture model developed by Morin and Grenier composed of
primary gingival fibroblasts embedded within a collagen
hydrogel and overlaid with phorbol 12-myristate 13-acetate
(PMA)-stimulated U937 cells that were responsive to
Aggregatibacter actinomycetemcomitans LPS treatment.18
Xiao et al. punched a hole in a full-thickness OME com-
posed of primary gingival fibroblasts, topped with the
HaCaT skin keratinocyte cell line and injected it with
LPS-stimulated, PMA-differentiated THP-1 cells to mimic
periodontal disease.20 Bao et al.22 developed a similar
FIG. 3. Viability of MDM within MDM-OME. Collagenase-treated OME (A) and MDM-OME (B) were stained with
APC-conjugated anti-CD11c to identify the presence of MDM. Cells identified as CD11c– (C) or CD11c+ (D) were gated
and assessed for viability. Graphs are representative of at least three independent experiments. APC, allophycocyanin. Color
images are available online.
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periodontal model using HPV E6/7-immortalized gingival
fibroblasts, keratinocytes, and MM6 cells to produce an
immune model that was then challenged with multispecies
bacterial biofilm to mimic subgingival plaque. To date,
Holmström et al. have developed the most characterized
immune-responsive OME. Their OME of gingival inflam-
mation were stimulated with LPS for several days to induce
peripheral blood monocyte differentiation in situ. Although
the OFK6/TERT-2 epithelium displayed a lack of differ-
entiation, as observed in previous publications,33 the pres-
ence of immune cells within the connective tissue was
confirmed by CD68 staining and their OME responded to
repeated LPS challenge with increased proinflammatory
cytokine expression.19
The importance of using primary human-derived macro-
phages in such in vitro models cannot be overstated. Many
studies examining macrophages have used monocytic can-
cer cell lines differentiated by culture with the potent protein
kinase C activator, PMA, to mimic these innate immune
cells. Although adequate and convenient for some assays,
these cell lines often fall short in terms of native phenotypic
and functional responses when compared with primary cells.
As a typical example, peripheral blood monocytes abun-
dantly express the archetypal cell surface marker and LPS
pattern recognition receptor CD14, whose expression is
notably decreased when these cells differentiate to MDM.
In contrast, undifferentiated THP-1 monocytes express neg-
ligible cell surface CD14 but following differentiation to a
macrophage morphology by PMA treatment, expression is
significantly increased,34,35 which affects their cellular re-
sponse to stimuli.24
Primary MDM cultured in a 3D environment responded
to E. coli LPS in a similar manner to 2D cultured MDM
in terms of cell surface marker expression and secretion of
proinflammatory cytokines. Moreover, 3D cultured MDM
displayed increased expression of the classical LPS-induced
M1 macrophage phenotypic markers CD80, CXCL8, and
IL-6, with simultaneously decreased expression of the M2
marker, CD206 similar to 2D polarized MDM,30 indicating
that these cells can be polarized in situ within a tissue-like
environment. Inhibition of this LPS-induced cytokine re-
sponse by the well-characterized anti-inflammatory gluco-
corticoid dexamethasone36 additionally indicates that MDM
within an in vitro stroma are amenable to drug treatment.
Interestingly, pretreatment with dexamethasone inhibited
TNF-a gene transcription in MDM 2D but not in any of the
3D culture systems, whereas TNF-a protein secretion was
inhibited to control levels in both 2D and 3D culture
FIG. 4. Immune response of MDM within an OME upon challenge with E. coli LPS. OME or MDM-OME were
challenged with LPS (500 ng/106 MDM) for 24 h following treatment for 4 h with or without Dex (1mg/mL). Gene expression
was analyzed by qPCR for markers of macrophage polarization (CD80, CD206, and CD163) and inflammation (TNF-a,
CXCL8, and IL-6), relative to B2M for OME (A) and for MDM-OME (B). Proinflammatory cytokine release was analyzed by
ELISA for TNF-a (C), CXCL8 (D), and IL-6 (E). Data are presented as mean–SD with statistically significance differences
determined using one-way ANOVA. *p< 0.05, **p< 0.01, ***p< 0.005; n= 3. Color images are available online.
IMMUNORESPONSIVE TISSUE-ENGINEERED ORAL MUCOSAL EQUIVALENTS 7
systems. Gewert et al. previously showed that pretreatment
with dexamethasone completely inhibited TNF-a protein
secretion in LPS-treated murine macrophages while TNF-a
mRNA was only partially inhibited.37 It is also possible that
MDM are less sensitive to dexamethasone and possibly
other drug treatments in 3D tissue culture environments than
2D, a phenomenon seen for other 3D culture systems.38
Incorporation of MDM into OME did not affect the tis-
sue architecture or histological characteristics of the tissue.
CD11c was found to be a reliable marker to separate MDM
from keratinocytes and fibroblasts by flow cytometry and in
conjunction with viability selection could be used effec-
tively to sort MDM into single-cell populations for further
downstream analysis such as establishment of MDM po-
larization status by multichromatic flow cytometry or single-
cell gene expression profiling.
The oral cavity is heavily colonized with more than 500
different species of microorganisms that constitute the com-
mensal oral microbiome,39 yet the oral epithelium remains
in a quiescent state in health because the epithelium is
predominantly nonresponsive to bacterial challenge at the
mucosal surface. Indeed, OME exposed to LPS displayed
similar levels of cytokine gene expression and protein sec-
tion to unstimulated controls, as observed previously.27 It is
the interaction between microbial mediators and innate im-
mune cells that reside in the epithelium or connective tissue
that are crucial for driving immunity, which is why incor-
poration of macrophages into OME is imperative if host
pathogen responses are to be replicated in vitro.
LPS induced a significant increase in TNF-a protein re-
lease in MDM-OME, compared with OME, which was pre-
vented by dexamethasone treatment, although this was not
matched by gene expression. This is likely due to the in vitro
models being sampled at 24 h, a time point where protein
secretion is maximal, but TNF-a mRNA expression may
have returned to baseline levels. Fluorescence imaging
showed that TNF-a was almost exclusively secreted from
MDM within the collagen connective tissue, underscoring
the importance of these innate immune cells in driving the
inflammatory response. Once secreted, TNF-a is a key me-
diator in initiating the immune response by inducing the
gene expression and protein secretion of an array of proin-
flammatory factors by neighboring cells, such as fibroblasts
and keratinocytes, which then further orchestrate inflam-
mation. This cascade effect was observed by the increased
gene expression of CXCL8 and IL-6 in MDM-OME but
FIG. 5. TNF-a secretion by MDM in MDM-OME. MDM-OME were challenged with LPS for 24 h following pretreat-
ment for 4 h with or without 1 mg/mL Dex+LPS; controls received no treatment. Immunofluorescence staining of tissue
sections was performed for CD68 (green), TNF-a (red), counterstained for nuclei with DAPI (blue), and images merged
(A). Panel (B) shows a magnified image of the white square displayed in LPS-treated MDM-OME in (A). Scale bars =
20 mm. Color images are available online.
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not OME after 24 h, as the MDM-secreted TNF-a stimulated
proinflammatory gene transcription in surrounding cells.
Protein secretion of CXCL8, but not IL-6, mirrored this
pattern in LPS-stimulated MDM-OME compared with OME
alone at 24 h. Cytokine release may increase further over
time as gene transcription progresses to translation and pro-
tein secretion, as was observed by Holmström et al. in their
OME of gingival inflammation that was stimulated repeat-
edly with LPS for several days.19
In acute inflammation, levels of TNF-a and other proin-
flammatory cytokines subside as infection is resolved. How-
ever, persistently high levels of TNF-a are observed in several
oral diseases such as oral lichen planus,40 periodontitis,19 and
oral squamous cell carcinoma,41 where the presence of mac-
rophages is heavily implicated in the disease process. Inclu-
sion ofMDM into OME represents an essential component of
both a healthy or disease model and will aid in the under-
standing of how these cells drive disease progression and how
the unresolved proinflammatory cascade can be modulated.
In conclusion, MDM are suitable for inclusion in tissue-
engineered OME and improve the functional response of
these models to inflammatory stimuli, notably the secretion
of MDM-derived TNF-a. This improved model system has
potential applications in several areas of oral bioscience in-
cluding oral mucosal responses to microorganisms and anal-
ysis of host–pathogen interactions, chronic inflammatory
conditions, drug delivery, or adverse reaction to biomaterials.
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